Evidence map›Paper›PMID 39516257›Full record

ArticleBJC reports2024

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.

Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, Chaorong Wu, Clinton Wu, Laura Huppert, Lauren S Levine, Paula Sison, Katy K Tsai, Melissa Chow and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Targeting platelet-tumor cell interactions: a novel approach to cancer therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zoe Quandt *Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Saya Jacob *Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Muhammad Zaki Hidayatullah FadlullahDepartments of Oncological Sciences and Biomedical Informatics, University of Utah, Salt Lake City, UT, 84112, USA.
Chaorong WuDivision of Epidemiology, University of Utah, Salt Lake City, UT, 84112, USA.
Clinton WuDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Laura HuppertDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Lauren S LevineDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Paula SisonDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Katy K TsaiDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Melissa ChowDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Jee Hye KangDiabetes Center, University of California San Francisco, San Francisco, CA, 94143, USA.
Jimmy HwangDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
James C LeeDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Ariel OglesbyDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Jessica VenegasHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, 84112, USA.
Ben J BrintzDivision of Epidemiology, University of Utah, Salt Lake City, UT, 84112, USA.
Aik Choon TanDepartments of Oncological Sciences and Biomedical Informatics, University of Utah, Salt Lake City, UT, 84112, USA.
Mark S AndersonDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
Michael D RosenblumDermatology, University of California San Francisco, San Francisco, CA, 94143, USA.
Arabella YoungDiabetes Center, University of California San Francisco, San Francisco, CA, 94143, USA. Arabella.Young@hci.utah.edu.ORCID http://orcid.org/0000-0002-6845-9753
Adil I DaudDepartment of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA. Adil.Daud@ucsf.edu.ORCID http://orcid.org/0000-0002-6617-8421

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAISSE, CHRISTIAN · 2003 to 2019
$21.8M
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026
$16.0M
UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6M
NCATS NIH HHS UM1 TR004409NCI NIH HHS K12 CA260225NIDDK NIH HHS K12 DK133995NIDDK NIH HHS P30 DK063720
6 · The paper itself

Abstract

objectiveMany patients with melanoma treated with immune checkpoint inhibitors (ICIs) do not derive response. Preclinical and retrospective studies identified that inhibition of the cyclooxygenase (COX) pathway may improve response to ICI treatment.

methodsThis prospective single site phase II trial accrued patients with advanced/metastatic melanoma. Participants underwent high-dose aspirin daily combined with pembrolizumab and ipilimumab every 3 weeks for 4 cycles followed by high-dose aspirin and pembrolizumab monotherapy. The primary endpoint was objective response rate (ORR). Longitudinal sampling of blood was performed to assess peripheral immune correlates.

resultsTwenty-seven subjects were enrolled with median follow-up of 32 months. An ORR of 62.9% was reached prior to discontinuation due to low likelihood of achieving the pre-specified ORR of 80%. 17 patients (63%) experienced a treatment-related adverse event (TRAEs) grade 3 or higher. A per-protocol analysis showed that patients able to continue aspirin alongside ICI through the induction period experienced significant survival benefit. Ten cytokines and increased regulatory T cells in the periphery correlated with beneficial response.

conclusionsThe addition of high-dose aspirin to combination ICI within this study results in response comparable to ICI alone. Future clinical studies of COX inhibition will need to focus on mitigation of AEs to establish the clinical utility of this combination.

Identifiers

PMID39516257
PMCPMC11524064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.